Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab [4]

Pediatric Infectious Disease Journal

Volumn 23, Issue 3, 2004, Pages 284-285

  Meissner, H Cody ^a   Rennels, Margaret B ^b   Pickering, Larry K ^c   Hall, Caroline B ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

High risk infants; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; PRACTICE GUIDELINES; PRIMARY PREVENTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK ASSESSMENT;

EID: 1542723730     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000121203.33560.f9     Document Type: Letter

References (12)

1. Shay DK, Holman RC, Newman RC, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalization among US children, 1980-1996. JAMA 1999;282:1440-6.
2. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997-1999. Pediatr Infect Dis J 2002;21:629-32.
3. Meissner HC, Long SS and American Academy of Pediatrics, Committee on Infectious Disease and Committee on Fetus and Newborn. Technical report: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1447-52.
4. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18:223-31.
5. Durbin AP, Karron RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 2003;37:1668-77.
6. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Fetus and Newborn. Technical report: prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-16.
7. American Academy of Pediatrics. Committee on Infect Dis and Committee on Fetus and Newborn. Policy report: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6.
8. Elhassan NO, Stevens TP, Sorbero MES, Dick AW, Guillet R, Hall CB. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease? Pediatr Infect Dis J 2003;22:939-42.
9. The IMPACT Study Group. Reduction of RSV hospitalization among premature infants and infants with BPD using respiratory syncytial virus monoclonal antibody prophylaxis. Pediatrics 1998;102:531-7.
10. Boyce TG, Mellen BG, Mitchel EF, Wright PE, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
11. Weisman LE. Populations at risk of developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Pediatr Infect Dis J 2003;22:S33-9.
12. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus infection. J Pediatr 2003;143:S112-17.